Business Context and Reporting Period
This Form 8-K was filed by SeaStar Medical Holding Corp on December 13, 2024, reporting a putative stockholder derivative action filed on the same date. The company is a Delaware corporation headquartered in Denver, Colorado, with common stock (ICU) and warrants (ICUCW) trading on The Nasdaq Stock Market LLC.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on legal proceedings and does not contain financial statement data.
Material Changes and Legal Proceedings
On December 13, 2024, a stockholder named Jose Lazo filed a derivative action (Lazo v. Schlorff et. al.) in the U.S. District Court for the District of Colorado. The complaint alleges:
- Violations of Section 14(a) of the Exchange Act and breaches of fiduciary duties by the CEO, former CFO, and certain directors.
- False and misleading statements regarding the prospects for FDA approval of the company's Selective Cytopheretic Device.
- Deficiencies in internal financial controls and improper accounting for financial instruments, which led to a restatement of previously issued financial statements.
- Claims under Section 10(b) and 21D of the Exchange Act against the CEO and former CFO.
The allegations are substantially similar to a federal putative class action complaint disclosed by the company on July 9, 2024.
Outlook, Risks, and Management Commentary
The company notes that additional stockholders may file substantially similar complaints in the future. Management has stated it will not make separate disclosures of such complaints unless they are materially different from the current Derivative Action. The lawsuit seeks damages, restitution on behalf of the company, and injunctive relief concerning corporate governance and internal controls.
Key Facts for Investor Verification
- Verify the status and potential financial impact of the pending derivative litigation filed on December 13, 2024.
- Review the details of the previously disclosed class action from July 9, 2024, to understand the continuity of allegations.
- Confirm the specifics of the financial restatement mentioned in the complaint regarding the classification of financial instruments.
- Monitor for any updates on the company's internal financial controls and corporate governance reforms.